Pharmacologic Substance
Veliparib
A poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with chemosensitizing and antitumor activities. With no antiproliferative effects as a single agent at therapeutic concentrations, ABT-888 inhibits PARPs, thereby inhibiting DNA repair and potentiating the cytotoxicity of DNA-damaging agents....
more
Viewing results
1 - 10 of 144,000 (0.27 seconds)
-
Dec 19, 2019 ... Combining PARP inhibitors with chemotherapy has been challenging because of hematologic toxic effects that result in substantial dose reductions ...
-
Aug 27, 2020 ... 2014; 32 (abstr 2570.) ... Veliparib selectively inhibits the polymerase activity of PARP without substantial trapping of PARP protein onto DNA ...
-
Jul 7, 2016 ... Veliparib–carboplatin plus standard therapy was considered for HER2-negative tumors and was therefore evaluated in 3 signatures.
-
A substance being studied in the treatment of breast cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the ...
-
Nov 10, 2021 ... Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, ...
-
The drug is designed to help delay clinical Type 1 diabetes in at-risk people. Provention found in clinical trials that teplizumab delayed disease onset by a ...
-
Veliparib is a benzimidazole substituted with a carbamoyl group at C-4 and a (2R)-2-methylpyrrolidin-2-yl moiety at C-2. It is a potent, orally bioavailable ...
-
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial ...
-
Veliparib (ABT-888) is a small molecule that inhibits PARP1 and PARP2 at nanomolar concentrations [48]. It has good bioavailability and has been shown to cross ...
-
PARP inhibitor veliparib, plus carboplatin and etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ED-.